chevron_leftBack
As of 24 April 2025, ME Therapeutics Holdings Inc. has a market cap of $170.2M USD, ranking #18000 globally and #465 in Canada. It ranks #1797 in the Healthcare sector, and #515 in the Biotechnology industry.
Key Stats
Market Cap
$170.2MUSD
235.71M CAD
Enterprise Value
$168.47MUSD
233.81M CAD
EBITDA (TTM)
-$985.96KUSD
-1.37M CAD
Net Income (TTM)
-$945.48KUSD
-1.31M CAD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Salim Dhanji
open_in_new
Founded
2014
Website
metherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | - | -14% | 20% | 55% | 142% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
METX
ME Therapeutics Holding Inc
ISIN: CA5527671054
Shares Out.:
Shares Outstanding:
26.189M1
Shares Float:
9.349M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
9.00 CAD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About ME Therapeutics Holdings Inc.
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno‐oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.
